FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mikael Oscarson

Research Profile

Chemicals & Drugs

Physiology

Genes & Molecular Sequences

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Michela Barbaro; Antonio Balsamo; Britt-Marie Anderlid; Anne Grethe Myhre; Monia Gennari; Annalisa Nicoletti; Maria Carla Pittalis; Mikael Oscarson; Anna Wedell
Characterization of deletions at 9p affecting the candidate regions for sex reversal and deletion 9p syndrome by MLPA.
Michela Barbaro; Alessandro Cicognani; A Balsamo; A Löfgren; L Baldazzi; Anna Wedell; Mikael Oscarson
Gene dosage imbalances in patients with 46,XY gonadal DSD detected by an in-house-designed synthetic probe set for multiplex ligation-dependent probe amplification analysis.
Mikael Oscarson; Oliver Burk; Stefan Winter; Matthias Schwab; Renzo Wolbold; Jürgen Dippon; Michel Eichelbaum; Urs A Meyer
Effects of rifampicin on global gene expression in human small intestine.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mikael Oscarson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Michela Barbaro; Antonio Balsamo; Britt-Marie Anderlid; Anne Grethe Myhre; Monia Gennari; Annalisa Nicoletti; Maria Carla Pittalis; Mikael Oscarson; Anna Wedell
Characterization of deletions at 9p affecting the candidate regions for sex reversal and deletion 9p syndrome by MLPA.
European journal of human genetics : EJHG 2009;17(11):1439-47.
2008: Michela Barbaro; Alessandro Cicognani; A Balsamo; A Löfgren; L Baldazzi; Anna Wedell; Mikael Oscarson
Gene dosage imbalances in patients with 46,XY gonadal DSD detected by an in-house-designed synthetic probe set for multiplex ligation-dependent probe amplification analysis.
Clinical genetics 2008;73(5):453-64.
2007: Mikael Oscarson; Oliver Burk; Stefan Winter; Matthias Schwab; Renzo Wolbold; Jürgen Dippon; Michel Eichelbaum; Urs A Meyer
Effects of rifampicin on global gene expression in human small intestine.
Pharmacogenetics and genomics 2007;17(11):907-18.
2007: Michela Barbaro; Mikael Oscarson; Jacqueline Schoumans; Johan Staaf; Sten-A Ivarsson; Anna Wedell
Isolated 46,XY gonadal dysgenesis in two sisters caused by a Xp21.2 interstitial duplication containing the DAX1 gene.
The Journal of clinical endocrinology and metabolism 2007;92(8):3305-13.
2007: Michela Barbaro; Mikael Oscarson; Ingrid Almskog; Hans Hamberg; Anna Wedell
Complete androgen insensitivity without Wolffian duct development: the AR-A form of the androgen receptor is not sufficient for male genital development.
Clinical endocrinology 2007;66(6):822-6.
2007: Sophie Bensing; Sergueï O Fetissov; Jan Mulder; Jaakko Perheentupa; Jan Gustafsson; Eystein S Husebye; Mikael Oscarson; Olov Ekwall; Patricia A Crock; Tomas Hökfelt; Anna-Lena Hulting; Kämpe Olle
Pituitary autoantibodies in autoimmune polyendocrine syndrome type 1.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(3):949-54.
2007: J Frygelius; Mikael Oscarson; K Nordqvist; Anna Wedell; Virpi Töhönen
The reproductive tissue specific cystatin subgroup of genes: expression during gonadal development in wildtype and testatin knockout animals.
Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation 2007;1(6):363-72.
2006: Mikael Oscarson; Uli Zanger; Oktay F Rifki; Kathrin Klein; Michel Eichelbaum; Urs A Meyer
Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine.
Clinical pharmacology and therapeutics 2006;80(5):440-456.
2005: Marià Pitarque; Cristina Rodríguez-Antona; Mikael Oscarson; Magnus Ingelman-Sundberg
Transcriptional regulation of the human CYP2A6 gene.
The Journal of pharmacology and experimental therapeutics 2005;313(2):814-22.
2004: Oliver Von Richter; Marià Pitarque; Cristina Rodríguez-Antona; Anna Testa; Roberto Mantovani; Mikael Oscarson; Magnus Ingelman-Sundberg
Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6).
Pharmacogenetics 2004;14(6):369-79.
2004: Maria Karlgren; Maria Backlund; Inger Johansson; Mikael Oscarson; Magnus Ingelman-Sundberg
Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1.
Biochemical and biophysical research communications 2004;315(3):679-85.
2004: Marià Pitarque; Oliver Von Richter; Cristina Rodríguez-Antona; Jue Wang; Mikael Oscarson; Magnus Ingelman-Sundberg
A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity.
Human mutation 2004;23(3):258-66.
2003: Tove Rylander-Rudqvist; Sara Wedren; Fredrik Granath; Keith Humphreys; Susanne Ahlberg; ELISABETE WEIDERPASS; Mikael Oscarson; Magnus Ingelman-Sundberg; Ingemar Persson
Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk.
Carcinogenesis 2003;24(9):1533-9.
2003: Mikael Oscarson
Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2003;41(4):573-80.
2002: Mikael Oscarson; Roman A McLellan; Vendela Asp; MariCarmen Ledesma; Maria Luisa Bernal Ruiz; Blanca Sinues; Arja Rautio; Magnus Ingelman-Sundberg
Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity.
Human mutation 2002;20(4):275-83.
2002: Eleni Aklillu; Mikael Oscarson; Mats Hidestrand; Brith Leidvik; Charlotta Otter; Magnus Ingelman-Sundberg
Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population.
Molecular pharmacology 2002;61(3):586-94.
2002: Mikael Oscarson; Magnus Ingelman-Sundberg
CYPalleles: a web page for nomenclature of human cytochrome P450 alleles.
Drug metabolism and pharmacokinetics 2002;17(6):491-5.
2002: Magnus Ingelman-Sundberg; Mikael Oscarson
Human CYP allele database: submission criteria procedures and objectives.
Methods in enzymology 2002;357():28-36.
2001: M Ingelman-Sundberg; Mikael Oscarson; A K Daly; S Garte; D W Nebert
Human cytochrome P-450 (CYP) genes: a web page for the nomenclature of alleles.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001;10(12):1307-8.
2001: Mats Hidestrand; Mikael Oscarson; Jarmo S Salonen; Leena Nyman; Olavi Pelkonen; M Turpeinen; Magnus Ingelman-Sundberg
CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(11):1480-4.
2001: Gunnel Tybring; Mats Hidestrand; Mikael Oscarson; Magnus Ingelman-Sundberg; Marja-Liisa Dahl; Erik Eliasson
Role of CYP2C9 polymorphism in losartan oxidation.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(7):1051-6.
2001: Marià Pitarque; Oliver Von Richter; B Oke; H Berkkan; Mikael Oscarson; Magnus Ingelman-Sundberg
Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity.
Biochemical and biophysical research communications 2001;284(2):455-60.
2001: A Westlind; S Malmebo; Inger Johansson; Charlotta Otter; Tommy B Andersson; Magnus Ingelman-Sundberg; Mikael Oscarson
Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43.
Biochemical and biophysical research communications 2001;281(5):1349-55.
2001: Umit Yasar; Mikael Oscarson; Erik Eliasson; Folke Sjöqvist
Mutations of the CYP2C9 gene and the response to warfarin.
Surgery 2001;129(3):384.
2001: T Rylander; Etienne P A Neve; Magnus Ingelman-Sundberg; Mikael Oscarson
Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1).
Biochemical and biophysical research communications 2001;281(2):529-35.
2001: Marie-Anne Loriot; S Rebuissou; Mikael Oscarson; Sylvie Cenée; M Miyamoto; Noritaka Ariyoshi; Tetsuya Kamataki; Denis Hémon; Philippe Beaune; Isabelle Stücker
Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population.
Pharmacogenetics 2001;11(1):39-44.
2001: Mikael Oscarson
Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(2):91-5.
2000: Roman A McLellan; Mikael Oscarson; Mats Hidestrand; Brith Leidvik; E Jonsson; Charlotta Otter; Magnus Ingelman-Sundberg
Characterization and functional analysis of two common human cytochrome P450 1B1 variants.
Archives of biochemistry and biophysics 2000;378(1):175-81.
2000: M Ingelman-Sundberg; A K Daly; Mikael Oscarson; D W Nebert
Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles.
Pharmacogenetics 2000;10(1):91-3.
1999: Mikael Oscarson; Roman A McLellan; H Gullstén; José Agúndez; Julio Benitez; Arja Rautio; Hannu Raunio; Olavi Pelkonen; Magnus Ingelman-Sundberg
Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.
FEBS letters 1999;460(2):321-7.
1999: Y Hu; J Hakkola; Mikael Oscarson; M Ingelman-Sundberg
Structural and functional characterization of the 5'-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene.
Biochemical and biophysical research communications 1999;263(2):286-93.
1999: Magnus Ingelman-Sundberg; Mikael Oscarson; Roman A McLellan
Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment.
Trends in pharmacological sciences 1999;20(8):342-9.
1999: Mikael Oscarson; Roman A McLellan; H Gullstén; Q Y Yue; M A Lang; M L Bernal; Blanca Sinues; A Hirvonen; Hannu Raunio; Olavi Pelkonen; Magnus Ingelman-Sundberg
Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population.
FEBS letters 1999;448(1):105-10.
1998: Mikael Oscarson; H Gullstén; Arja Rautio; M L Bernal; Blanca Sinues; Marja-Liisa Dahl; J H Stengård; Olavi Pelkonen; Hannu Raunio; Magnus Ingelman-Sundberg
Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase.
FEBS letters 1998;438(3):201-5.
1997: Mikael Oscarson; Mats Hidestrand; Inger Johansson; Magnus Ingelman-Sundberg
A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.
Molecular pharmacology 1997;52(6):1034-40.
1997: Roman A McLellan; Mikael Oscarson; Anna-Karin Alexandrie; J Seidegård; D A Evans; Agneta Rannug; Magnus Ingelman-Sundberg
Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity.
Molecular pharmacology 1997;52(6):958-65.
1997: Roman A McLellan; Mikael Oscarson; J Seidegård; D A Evans; Magnus Ingelman-Sundberg
Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians.
Pharmacogenetics 1997;7(3):187-91.
1997: Y Hu; Mikael Oscarson; Inger Johansson; Q Y Yue; M L Dahl; M Tabone; S Arincò; E Albano; Magnus Ingelman-Sundberg
Genetic polymorphism of human CYP2E1: characterization of two variant alleles.
Molecular pharmacology 1997;51(3):370-6.
1994: Inger Johansson; Mikael Oscarson; Q Y Yue; L Bertilsson; F Sjöqvist; Magnus Ingelman-Sundberg
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
Molecular pharmacology 1994;46(3):452-9.
1994: Magnus Ingelman-Sundberg; Inger Johansson; I Persson; Mikael Oscarson; Y Hu; L Bertilsson; M L Dahl; F Sjöqvist
Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicity.
EXS 1994;71():197-207.